-
The era of second-generation drug-eluting stent (DES) technology moved one step closer to reality last month with a recommendation to the FDA by its cardiovascular system panel to approve the Endeavor DES from Medtronic (Minneapolis).
-
Largely at the prodding of industry, FDA has pondered whether it should grant device makers greater leeway in the use of clinical trials other than the gold standard of randomized, controlled trials (RCTs).
-
Ariad Pharmaceuticals reported that it has entered a nonexclusive license agreement with Icon Medical to develop drug-eluting stents that deliver Ariad's mTOR inhibitor, deforolimus, to prevent restenosis of injured vessels following angioplasty /stenting.
-
When it comes to being an effective, professional and ethical case manager, it all boils down to being a good advocate for your clients, John Banja, PhD, asserts.
-
A Medicare demonstration project at Montefiore Medical Center in New York City provides care coordination to help high-cost, fee-for-service beneficiaries comply with their medical treatment plan and access the community services they need to manage their chronic conditions.
-
Blue Cross Blue Shield of Rhode Island's case management department consistently scores in the 90th percentile on satisfaction surveys sent to members who have completed a case management program.
-
Choosing February as American Heart Month is not coincidental. With Valentine's Day in February, it is a month in which people are heart-centric, in the spirit of honoring the emotional needs of the heart.
-
Antibiotic-resistant infections are not new to the health care setting, but headlines throughout the country have increased public awareness of the potential risk of infection.
-
Improving the health of patients in your hospital is a large enough challenge, but imagine taking on the well-being of an entire city.
-
